Cargando…

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations

BACKGROUND: Immunotherapy using programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors seems less effective in non-small cell lung cancer (NSCLC) patients with epithelial growth factor receptor (EGFR) mutations. Varied responses to PD-1/PD-L1 inhibitors have recently been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Tiantian, Jiao, Jin, Huo, Ran, Li, Xiaofang, Fang, Guotao, Zhao, Qi, Liu, Weiwei, Han, Xiao, Xi, Chenglin, Wang, Yanan, Shang, Yanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389166/ https://www.ncbi.nlm.nih.gov/pubmed/35992815 http://dx.doi.org/10.3389/fonc.2022.922899

Ejemplares similares

Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients
por: Shang, Yanhong, et al.
Publicado: (2023)

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
por: Bai, Lu, et al.
Publicado: (2023)

Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma
por: Kang, Kai, et al.
Publicado: (2020)

Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma
por: Li, Lin, et al.
Publicado: (2023)

Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report
por: Fang, Guotao, et al.
Publicado: (2022)

Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib
por: Shang, Yanhong, et al.
Publicado: (2020)

Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors
por: Wang, Zi‐Ming, et al.
Publicado: (2021)

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma
por: Aili, Abudureyimujiang, et al.
Publicado: (2021)

Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis
por: Yan, Junya, et al.
Publicado: (2020)

Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features
por: Wen, Qiang, et al.
Publicado: (2021)

Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden
por: Yuan, Hong, et al.
Publicado: (2021)

The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells
por: Yan, Xiaotian, et al.
Publicado: (2021)

Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung Cancer
por: Qiu, Yuan, et al.
Publicado: (2021)

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2021)

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
por: Guo, Zixin, et al.
Publicado: (2021)

Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer
por: Xiao, Weikai, et al.
Publicado: (2021)

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
por: Duan, Xiao-Peng, et al.
Publicado: (2023)

High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations
por: Wang, Jianlei, et al.
Publicado: (2022)

Relevance of STK11 Mutations Regarding Immune Cell Infiltration, Drug Sensitivity, and Cellular Processes in Lung Adenocarcinoma
por: Li, Zhenqing, et al.
Publicado: (2020)

Insights Into the Somatic Mutation Burden of Hepatoblastomas From Brazilian Patients
por: Aguiar, Talita Ferreira Marques, et al.
Publicado: (2020)

Impact of Low-Burden TP53 Mutations in the Management of CLL
por: Lazarian, Gregory, et al.
Publicado: (2022)

Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy
por: Zeng, Lisi, et al.
Publicado: (2022)

SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer
por: Harbin, Laura M., et al.
Publicado: (2023)

Somatic mutations of thymic epithelial tumors with myasthenia gravis
por: Pardini, Eleonora, et al.
Publicado: (2023)

Germline Mutational Landscape in Chinese Patients With Advanced Breast Cancer
por: Zhang, Jiayang, et al.
Publicado: (2022)

APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer
por: Natesan, Divya, et al.
Publicado: (2022)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
por: Wang, Peipei, et al.
Publicado: (2021)

Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer
por: Zhou, Li, et al.
Publicado: (2021)

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
por: Lin, Chen, et al.
Publicado: (2020)

Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
por: Wen, Wei Xiong, et al.
Publicado: (2019)

Transcriptomic and Mutational Analysis Discovering Distinct Molecular Characteristics Among Chinese Thymic Epithelial Tumor Patients
por: Liang, Naixin, et al.
Publicado: (2021)

Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
por: Jiang, Tao, et al.
Publicado: (2019)

Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients
por: Guo, Gang, et al.
Publicado: (2021)

A Novel Germline SDHA Gene Mutation and Co-Occurring Somatic KIT Activating Mutation in a Patient With Pediatric Central Nervous System Germ Cell Tumor: Case Report
por: Yue, Xizan, et al.
Publicado: (2022)

Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Ma, Yuhui, et al.
Publicado: (2021)

Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells
por: Zhang, Qian, et al.
Publicado: (2019)

MicroRNAs Expression Patterns Predict Tumor Mutational Burden in Colorectal Cancer
por: Huang, Jiahao, et al.
Publicado: (2021)

miRNA-Based Signature Associated With Tumor Mutational Burden in Colon Adenocarcinoma
por: Xue, Weijie, et al.
Publicado: (2021)

Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling
por: Leong, Tracy L., et al.
Publicado: (2023)

Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8(+) T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer
por: Shuai, Chong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b77ov9f3pnq4kt4kg5rcrfn5u8